Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.
The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Endocrine system - commissioning policiesAlogliptin (Vipidia®) tablets for the treatment of type 2 diabetes Dulaglutide (Trulicity®) for the treatment of type 2 diabetes FreeStyle Libre for interstitial glucose monitoring in diabetes Insulin Degludec (Tresiba®) for Type 1 Diabetes Insulin Degludec (Tresiba®) for Type 2 Diabetes Lixisenatide for type 2 diabetes
Please note: Some commissioning policies approved by the previous commissioning organisations have not been reviewed and updated yet. However they are still applicable for the local population and can be accessed here.